Aldosterone Excretion among Subjects with Resistant Hypertension and Symptoms of Sleep Apnea

Chest

Volumn 125, Issue 1, 2004, Pages 112-117

  Calhoun, David A ^b,d   Nishizaka, Mari K ^a   Zaman, Mohammad A ^a   Harding, Susan M ^c  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d NONE   (United States)

Author keywords

Hyperaldosteronism; Hypertension; Renin; Sleep apnea

Indexed keywords

ALDOSTERONE; SODIUM CHLORIDE;

ADULT; AGED; ALDOSTERONE BLOOD LEVEL; ALDOSTERONE URINE LEVEL; ARTICLE; CONTROLLED STUDY; DIET; EVALUATION; EXCRETION; FEMALE; HEALTH SURVEY; HEMOCONCENTRATION; HIGH RISK PATIENT; HIGH SODIUM INTAKE; HUMAN; HYPERTENSION; INGESTION; MAJOR CLINICAL STUDY; MALE; PATIENT REFERRAL; PLASMA RENIN ACTIVITY; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; PROBABILITY; PROSPECTIVE STUDY; RISK ASSESSMENT; SLEEP APNEA SYNDROME; SODIUM URINE LEVEL; SYMPTOM; TIME; UNIVERSITY HOSPITAL; URINARY EXCRETION;

EID: 1442307014     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.125.1.112     Document Type: Article

References (37)

1. Peppard PE, Young T, Palta M, et al. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med 2000; 342:1378-1384
2. Logan AG, Perlikowski SM, Mente A, et al. High prevalence of unrecognized sleep apnoea in drug-resistant hypertension. J Hypertens 2001; 19:1-7
3. Lavie P, Hoffstein V. Sleep apnea syndrome: a possible contributing factor to resistant hypertension. Sleep 2001; 24:721-725
4. Kaplan NM. Hypokalemia in the hypertensive patient-with observations on the incidence of primary aldosteronism. Ann Intern Med 1967; 66:1079-1090
5. Andersen GS, Toftdahl DB, Lund JO, et al. The incidence rate of phaeochromocytoma and Conn's syndrome in Denmark, 1977-1981. J Hum Hypertens 1988; 2:187-189
6. Gordon RD, Stowasser M, Tunny TJ, et al. High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol 1994; 21:315-318
7. Gordon RD, Ziesak MD, Tunny TJ, et al. Evidence that primary aldosteronism may not be uncommon: 12% incidence among antihypertensive drug trial volunteers. Clin Exp Pharmacol Physiol 1993; 20:296-298
8. Fardella CE, Mosso L, Gómez-Sánchez C, et al. Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab 2000; 85:1863-1867
9. Rayner BL, Opie LH, Davidson JS. The aldosterone/renin ratio as a screening test for primary aldosteronism. S Afr Med J 2000; 90:394-400
10. Lim PO, Dow E, Brennan G, et al. High prevalence of primary aldosteronism in the Tayside hypertension clinic population. J Hum Hypertens 2000; 14:311-315
11. Lim PO, Rodgers P, Cardale K, et al. Potentially high prevalence of primary aldosteronism in a primary-care population [letter]. Lancet 1999; 353:40
12. Rossi E, Regolisti G, Negro A, et al. High prevalence of primary aldosteronism using postcaptopril plasma aldosterone to renin ratio as a screening test among Italian hypertensives. Am J Hypertens 2002; 15:896-902
13. Calhoun DA, Nishizaka MK, Zaman MA, et al. High prevalence of primary aldosteronism among black and white subjects with resistant hypertension. Hypertension 2002; 40:892-896
14. Thakkar RB, Oparil S. Primary aldosteronism: a practical approach to diagnosis and treatment. J Clin Hypertens 2001; 3:189-195
15. Young WF Jr. Primary aldosteronism: a common and curable form of hypertension. Cardiol Rev 1999; 7:207-214
16. Netzer NC, Stoohs RA, Netzer CM, et al. Using the Berlin Questionnaire to identify patients at risk for the sleep apnea syndrome. Ann Intern Med 1999; 131:485-491
17. Young T, Peppard PE, Gottlieb DJ. Epidemiology of obstructive sleep apnea: a population health perspective. Am J Respir Crit Care Med 2002; 165:1217-1239
18. Grote L, Ploch T, Heitmann J, et al. Sleep-related breathing disorder is an independent risk factor for systemic hypertension. Am J Respir Crit Care Med 1999; 160:1875-1882
19. Horner RL, Brooks D, Kozar LF, et al. Immediate effects of arousal from sleep on cardiac autonomic outflow in the absence of breathing in dogs. J Appl Physiol 1995; 79:151-162
20. Dimsdale JE, Ziegler MG, Ancoli-Israel S, et al. The effect of sleep apnea on plasma and urinary catecholamines. Sleep 1995; 18:377-381
21. Phillips BG, Narkiewicz K, Pesek CA, et al. Effects of obstructive sleep apnea on endothelin-1 and blood pressure. J Hypertens 1999; 17:61-66
22. Flectcher EC, Lesske J, Culman J, et al. Sympathetic denervation blocks blood pressure elevation in episodic hypoxia. Hypertension 1992; 20:612-619
23. Carlson JT, Hedner J, Elam M, et al. Augmented resting sympathetic activity in awake patients with obstructive sleep apnea. Chest 1993; 103:1763-1768
24. Voogel AJ, van Steenwijk RP, Karemaker JM, et al. Effects of treatment of obstructive sleep apnea on circadian hemodynamics. J Auton Nerv Syst 1999; 77:177-183
25. Narkiewicz K, Kato M, Phillips BG, et al. Nocturnal continuous positive airway pressure decreases daytime sympathetic traffic in obstructive sleep apnea. Circulation 1999; 100:2332-2335
26. Gallay BJ, Ahmad S, Xu L, et al. Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. Am J Kidney Dis 2001; 37:699-705
27. Raff H, Roarty TP. Renin, ACTH, and aldosterone during acute hypercapnia and hypoxia in conscious rats. Am J Physiol 1988; 254:R431-R435
28. Maillard D, Fineyre F, Dreyfuss D, et al. Pressure-heart rate responses to α-adrenergjc stimulation and hormonal regulation in normotensive patients with obstructive sleep apnea. Am J Hypertens 1997; 10:24-31
29. Follenius M, Krieger J, Krauth MO, et al. Obstructive sleep apnea treatment: peripheral and central effects on plasma renin activity and aldosterone. Sleep 1991; 14:211-217
30. Saarelainen S, Hasan J, Siitonen S, et al. Effect of CPAP treatment on plasma volume, aldosterone and 24-h blood pressure in obstructive sleep apnea. J Sleep Res 1996; 5:181-185
31. Tishler PV, Larkin EK, Schluchter MD, et al. Incidence of sleep-disorder breathing in an urban adult population: the relative importance of risk factors in the development of sleep-disordered breathing. JAMA 2003; 289:2230-2237
32. Redline S, Tishler PV, Hans MG, et al. Racial differences in sleep-disordered breathing in African-Americans and Caucasians. Am J Respir Crit Care Med 1997; 155:186-192
33. Tuck ML, Sowers J, Dornfeld L, et al. The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients. N Engl J Med 1981; 304:930-933
34. Sowers JR, Nyby M, Stern N, et al. Blood pressure and hormone changes associated with weight reduction in the obese. Hypertension 1982; 4:686-691
35. Egan BM, Stepniakowski K, Goodfriend TL. Renin and aldosterone are higher and the hyperinsulinemic effect of salt restriction greater in subjects with risk factors clustering. Am J Hypertens 1994; 7:886-893
36. Goodfriend TL, Egan BM, Kelly DE. Plasma aldosterone, plasma lipoproteins, obesity and insulin resistance in humans. Prostaglandins Leukot Essent Fatty Acids 1999; 60:401-405
37. Goodfriend TL, Egan BM, Kelley DE. Aldosterone in obesity. Endocr Res 1998; 24:789-796